

# Henry C Kitchener

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/378808/publications.pdf>

Version: 2024-02-01

49  
papers

6,381  
citations

236925

25  
h-index

214800

47  
g-index

51  
all docs

51  
docs citations

51  
times ranked

7722  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ovarian cancer. <i>Lancet, The</i> , 2014, 384, 1376-1388.	13.7	1,491
2	Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. <i>Lancet, The</i> , 2014, 383, 524-532.	13.7	1,282
3	Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. <i>Lancet Oncology, The</i> , 2012, 13, 89-99.	10.7	584
4	Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 3388-3397.	1.6	398
5	HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. <i>Lancet Oncology, The</i> , 2009, 10, 672-682.	10.7	343
6	Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. <i>Modern Pathology</i> , 2015, 28, 836-844.	5.5	343
7	Chapter 7: Achievements and limitations of cervical cytology screening. <i>Vaccine</i> , 2006, 24, S63-S70.	3.8	179
8	A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: Extended follow up in the ARTISTIC trial. <i>European Journal of Cancer</i> , 2011, 47, 864-871.	2.8	163
9	Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. <i>Lancet, The</i> , 2014, 384, 2213-2227.	13.7	153
10	The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome. <i>Genetics in Medicine</i> , 2019, 21, 2390-2400.	2.4	153
11	Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. <i>Lancet Infectious Diseases, The</i> , 2016, 16, 1154-1168.	9.1	148
12	The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. <i>Health Technology Assessment</i> , 2014, 18, 1-196.	2.8	112
13	Primary cervical screening with high risk human papillomavirus testing: observational study. <i>BMJ: British Medical Journal</i> , 2019, 364, l240.	2.3	110
14	Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial. <i>Vaccine Journal</i> , 2015, 22, 361-373.	3.1	89
15	The impact of obesity and bariatric surgery on circulating and tissue biomarkers of endometrial cancer risk. <i>International Journal of Cancer</i> , 2019, 144, 641-650.	5.1	87
16	Working together to shape the endometrial cancer research agenda: The top ten unanswered research questions. <i>Gynecologic Oncology</i> , 2016, 143, 287-293.	1.4	77
17	Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies. <i>Modern Pathology</i> , 2017, 30, 459-468.	5.5	53
18	Anxiety and distress following receipt of results from routine HPV primary testing in cervical screening: The psychological impact of primary screening (PIPS) study. <i>International Journal of Cancer</i> , 2020, 146, 2113-2121.	5.1	52

#	ARTICLE	IF	CITATIONS
19	Risk of Newly Detected Infections and Cervical Abnormalities in Women Seropositive for Naturally Acquired Human Papillomavirus Type 16/18 Antibodies: Analysis of the Control Arm of PATRICIA. <i>Journal of Infectious Diseases</i> , 2014, 210, 517-534.	4.0	45
20	Cross-sectional study of HPV testing in self-sampled urine and comparison with matched vaginal and cervical samples in women attending colposcopy for the management of abnormal cervical screening. <i>BMJ Open</i> , 2019, 9, e025388.	1.9	43
21	PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial. <i>Clinical Cancer Research</i> , 2019, 25, 2424-2432.	7.0	41
22	HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT. <i>Health Technology Assessment</i> , 2019, 23, 1-44.	2.8	41
23	Colposcopy is not necessary to assess the risk to the cervix in HIV-positive women: An international cohort study of cervical pathology in HIV-positive women. <i>International Journal of Cancer</i> , 2007, 121, 2484-2491.	5.1	37
24	A cluster randomised trial of strategies to increase cervical screening uptake at first invitation (STRATEGIC). <i>Health Technology Assessment</i> , 2016, 20, 1-138.	2.8	36
25	Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative. <i>Modern Pathology</i> , 2018, 31, 1851-1861.	5.5	35
26	Developing role of HPV in cervical cancer prevention. <i>BMJ</i> , The, 2013, 347, f4781-f4781.	6.0	26
27	16/18 genotyping in triage of persistent human papillomavirus infections with negative cytology in the English cervical screening pilot. <i>British Journal of Cancer</i> , 2019, 121, 455-463.	6.4	24
28	Measurement of Neutralizing Serum Antibodies of Patients Vaccinated with Human Papillomavirus L1 or L2-Based Immunogens Using Furin-Cleaved HPV Pseudovirions. <i>PLoS ONE</i> , 2014, 9, e101576.	2.5	22
29	Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies. <i>Vaccine Journal</i> , 2015, 22, 806-816.	3.1	19
30	Human T cell responses to HPV 16 E2 generated with monocyte-derived dendritic cells. <i>International Journal of Cancer</i> , 2001, 94, 807-812.	5.1	16
31	Clinical performance of RNA and DNA based HPV testing in a colposcopy setting: Influence of assay target, cut off and age. <i>Journal of Clinical Virology</i> , 2014, 59, 104-108.	3.1	16
32	Psychological Impact of Primary Screening (PIPS) for HPV: a protocol for a cross-sectional evaluation within the NHS cervical screening programme. <i>BMJ Open</i> , 2016, 6, e014356.	1.9	14
33	Attendance at early recall and colposcopy in routine cervical screening with human papillomavirus testing. <i>International Journal of Cancer</i> , 2021, 148, 1850-1857.	5.1	14
34	Sexual behavior and HPV infection in British women, by postal questionnaires and telephone interviews. <i>Journal of Medical Virology</i> , 2011, 83, 1238-1246.	5.0	13
35	Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data. <i>BMJ</i> , The, 0, , e068776.	6.0	13
36	Urine testing for HPV. <i>BMJ</i> , The, 2014, 349, g5542-g5542.	6.0	12

#	ARTICLE	IF	CITATIONS
37	The Cervix Cancer Research Network: A Global Outreach Effort on Behalf of the Gynecologic Cancer InterGroup. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 506-508.	0.8	12
38	Urocortin suppresses endometrial cancer cell migration via CRFR2 and its system components are differentially modulated by estrogen. <i>Cancer Medicine</i> , 2017, 6, 408-415.	2.8	11
39	PROgesterone Therapy for Endometrial Cancer Prevention in Obese Women (PROTEC) Trial: A Feasibility Study. <i>Cancer Prevention Research</i> , 2021, 14, 263-274.	1.5	11
40	Age-specific outcomes from the first round of HPV screening in unvaccinated women: Observational study from the English cervical screening pilot. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 1278-1288.	2.3	10
41	The Cervix Cancer Research Network: Increasing Access to Cancer Clinical Trials in Low- and Middle-Income Countries. <i>Frontiers in Oncology</i> , 2015, 5, 14.	2.8	9
42	The PapilloCheck Assay for Detection of High-Grade Cervical Intraepithelial Neoplasia. <i>Journal of Clinical Microbiology</i> , 2015, 53, 3553-3559.	3.9	9
43	The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening pilot. <i>British Journal of Cancer</i> , 2022, 127, 278-287.	6.4	9
44	The modern management of endometrial cancer. <i>Oncology Reviews</i> , 2007, 1, 103-119.	1.8	8
45	A study of cellular counting to determine minimum thresholds for adequacy for liquid-based cervical cytology using a survey and counting protocol. <i>Health Technology Assessment</i> , 2015, 19, 1-64.	2.8	8
46	Cervical screening in 20-24-year olds. <i>Journal of Medical Screening</i> , 2006, 13, 62-63.	2.3	5
47	Implementation of prophylactic HPV vaccination: progress and future challenges. <i>Expert Review of Obstetrics and Gynecology</i> , 2010, 5, 591-603.	0.4	3
48	To promote maintenance or treatment, is that the question?. <i>Lancet Oncology</i> , The, 2017, 18, 1151-1152.	10.7	1
49	Recent advances in the treatment of advanced or recurrent endometrial cancer. <i>Expert Review of Obstetrics and Gynecology</i> , 2009, 4, 521-532.	0.4	0